Literature DB >> 24046827

Increased expression of CIP2A in cholangiocarcinoma and correlation with poor prognosis.

Peng Xu, Qiang Huang, Fang Xie, Xiao-Lan Xu, Feng Shao.   

Abstract

BACKGROUND/AIMS: To explore the expression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cholangiocarcinoma tissues and adjacent non-cancerous normal bile duct tissues, and to investigate the clinicopathological signinficance of the CIP2A protein in cholangiocarcinoma patients.
METHODOLOGY: Immunohistochemical staining was used to detect the expression of CIP2A protein in 57 cases (35 men and 22 women) of cholangiocarcinoma samples and 23 cases of para-cancerous normal bile duct samples. The results were analyzed with clinicopathological patameters and overall median survival time.
RESULTS: The positive rate of CIP2A protein expression in cholangiocarcinoma tissues was significantly higher than para-cancerous normal bile duct tissues. The expression of CIP2A was found to be not correlated with age, gender, smoking, grading, staging, lymph node metastasis, tumor site and hepatitis B virus (HBV) (p>0.05). Kaplan-Meier survival analysis showed that the overall survival time in patients with positive expression of CIP2A protein were shorter than in patients with negative expression of CIP2A (long rank=5.180, p=0.023). COX regression analysis implied that expression of CIP2A protein was an independent prognostic factor for cholangiocarcinoma patients (p<0.05).
CONCLUSIONS: CIP2A is overexpressed in human cholangiocarcinoma tissues, and overexpression of CIP2A correlates with poor prognosis. CIP2A expression may be a potential marker for biological malignancy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24046827

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  5 in total

1.  CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.

Authors:  Juandong Wang; Tao Huang; Jianzhi Sun; Yuan Yu; Zhifang Liu; Wenjuan Li; Jihui Jia; Chunyan Chen
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

Review 2.  Regulation of PP2A by Sphingolipid Metabolism and Signaling.

Authors:  Joshua Oaks; Besim Ogretmen
Journal:  Front Oncol       Date:  2015-01-15       Impact factor: 6.244

3.  CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.

Authors:  Peng Xu; Jie Yao; Jin He; Long Zhao; Xiaodong Wang; Zhennan Li; Jianjun Qian
Journal:  Oncotarget       Date:  2016-03-22

Review 4.  Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.

Authors:  Pradip De; Jennifer Carlson; Brian Leyland-Jones; Nandini Dey
Journal:  Oncotarget       Date:  2014-07-15

5.  Prognostic significance of CIP2A expression in solid tumors: A meta-analysis.

Authors:  Min Tang; Jiao-Feng Shen; Ping Li; Li-Na Zhou; Ping Zeng; Xi-Xi Cui; Min-Bin Chen; Ye Tian
Journal:  PLoS One       Date:  2018-07-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.